Janssen Biotech, Inc., a Johnson & Johnson company, has entered into a worldwide exclusive license and collaboration agreement with Protagonist Therapeutics, Inc. to develop, manufacture and commercialize PTG-200, a first-in-class, oral interleukin-23 receptor (IL-23R) antagonist drug candidate in development for the treatment of Crohn’s disease and ulcerative colitis (UC). PTG-200 is currently in Investigational New Drug (IND) enabling studies and the initiation of a Phase I trial is ...